Vera Therapeutics (VERA) said Monday it has secured an exclusive license deal with Stanford University for fusion protein targeting BAFF and APRIL, known as VT-109, with therapeutic potential across the spectrum of B cell mediated diseases.
Vera said it will develop and market VT-109 in exchange for undisclosed upfront and milestone payments as part of the agreement.
Vera's lead product candidate is atacicept, a fusion protein that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including Berger's disease and lupus nephritis.
The company's shares were down over 10% in recent trading.
Price: 33.26, Change: -3.77, Percent Change: -10.17
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。